A New Bevacizumab Carrier for Intravitreal Administration: Focus on Stability

Bevacizumab (BVZ) is a monoclonal antibody that binds to human vascular endothelial growth factor A (VEGF-A) and inhibits the interaction between VEGF-A and VEGF receptors, thus blocking the angiogenesis. Repeated intravitreal injections of BVZ for the treatment of ocular pathologies that present an...

Descripción completa

Detalles Bibliográficos
Autores principales: Chirio, Daniela, Peira, Elena, Sapino, Simona, Chindamo, Giulia, Oliaro-Bosso, Simonetta, Adinolfi, Salvatore, Dianzani, Chiara, Baratta, Francesca, Gallarate, Marina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8071554/
https://www.ncbi.nlm.nih.gov/pubmed/33921167
http://dx.doi.org/10.3390/pharmaceutics13040560

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8071554/
https://www.ncbi.nlm.nih.gov/pubmed/33921167
http://dx.doi.org/10.3390/pharmaceutics13040560

Ejemplares similares